SCHEMBL6669846

SCHEMBL6669846

Cc1ccccc1S(=O)(=O)N[C@@H](CC(=O)O)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ITGAV P06756 7/20 0.66
SLC1A3 P43003 1/20 0.58
SLC1A2 P43004 1/20 0.58
SLC1A1 P43005 1/20 0.58
ITGA2 P17301 1/20 0.57
CASP1 P29466 4/20 0.55
L3MBTL1 Q9Y468 2/20 0.52
ATM Q13315 1/20 0.52
ALDH1A1 P00352 2/20 0.51
CYP2C19 P33261 1/20 0.51
ITGB3 P05106 1/20 0.47
POLB P06746 1/20 0.47
MMP9 P14780 1/20 0.45
MMP8 P22894 1/20 0.45
MMP13 P45452 1/20 0.45
ADAMTS4 O75173 1/20 0.45
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6669839 1.00 ITGAV (0.66) ITGAVSLC1A3SLC1A2SLC1A1ITGA2
SCHEMBL3898279 0.87 ITGAV (0.67) ITGAVSLC1A3SLC1A2SLC1A1ITGA2
SCHEMBL27692486 0.87 ITGAV (0.67) ITGAVSLC1A3SLC1A2SLC1A1ITGA2
SCHEMBL1509337 0.86 ITGAV (0.63) ITGAVSLC1A3SLC1A2SLC1A1ITGA2
SCHEMBL1509340 0.86 ITGAV (0.63) ITGAVSLC1A3SLC1A2SLC1A1ITGA2
SCHEMBL5502394 0.84 POLB (0.66) ITGAVSLC1A3SLC1A2SLC1A1ITGA2
SCHEMBL6670956 0.84 POLB (0.66) ITGAVSLC1A3SLC1A2SLC1A1ITGA2
SCHEMBL3969631 0.84 ALDH1A1 (0.71) ITGAVSLC1A3SLC1A2SLC1A1ITGA2
SCHEMBL3969622 0.84 ALDH1A1 (0.71) ITGAVSLC1A3SLC1A2SLC1A1ITGA2
SCHEMBL7416663 0.82 SLC1A3 (0.62) ITGAVSLC1A3SLC1A2SLC1A1ITGA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1457487-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES Toray Fine Chemicals Co., Ltd. (JP) 2004-09-15 EP claimed
US-20040171836-A1 Method for producing optical-active cis-piperidine derivatives TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) 2004-09-02 US claimed
EP-1457487-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES Toray Fine Chemicals Co., Ltd. (JP) 2004-09-15 EP disclosed
US-20040171836-A1 Method for producing optical-active cis-piperidine derivatives TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) 2004-09-02 US disclosed
EP-0132373-B1 A NEUTRAL AMINO ACID COMPLEX AND A METHOD FOR OPTICAL RESOLUTION OF A DL-AMINO ACID AJINOMOTO CO., INC. (JP) 1988-10-05 EP disclosed
US-4610827-A Amino acid complex and a method for optical resolution of a DL-amino acid AJINOMOTO CO., INC. (JP) 1986-09-09 US disclosed
EP-0132373-A1 A neutral amino acid complex and a method for optical resolution of a DL-amino acid AJINOMOTO CO., INC. (JP) 1985-01-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171836-A1 Method for producing optical-active cis-piperidine derivatives TYR, DDC, TARBP1 ITGAV 4557/4885SLC1A3 613/4885SLC1A2 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.